Adaptimmune Therapeutics (ADAP)
(Real Time Quote from BATS)
$1.02 USD
-0.03 (-2.86%)
Updated May 23, 2024 03:54 PM ET
After-Market: $1.02 0.00 (0.00%) 4:12 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ADAP 1.02 -0.03(-2.86%)
Will ADAP be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ADAP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADAP
Adaptimmune (ADAP) Down on End of Collaboration With Roche
Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
ADAP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
Adaptimmune Therapeutics PLC (ADAP) Loses -28.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for ADAP
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Ionis Pharmaceuticals (IONS) and Ultragenyx Pharmaceutical (RARE)
Adaptimmune price target lowered by $6 at Mizuho, here's why
Analysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF), Adaptimmune Therapeutics (ADAP) and GoodRx Holdings (GDRX)
Analysts Conflicted on These Healthcare Names: Fortress Biotech (FBIO), GoodRx Holdings (GDRX) and Adaptimmune Therapeutics (ADAP)
ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q1 2024